Literature DB >> 36064576

Silencing TRAIP suppresses cell proliferation and migration/invasion of triple negative breast cancer via RB-E2F signaling and EMT.

Yan Zheng1, Huiqing Jia1,2, Ping Wang1, Litong Liu1, Zhaoxv Chen1,2, Xiaoming Xing2, Jin Wang1, Xiaohua Tan1, Chengqin Wang3,4.   

Abstract

TRAIP, as a 53 kDa E3 ubiquitin protein ligase, is involved in various cellular processes and closely related to the occurrence and development of tumors. At present, few studies on the relationship between TRAIP and triple negative breast cancer (TNBC) were reported. Bioinformatic analysis and Western blot, immunohistochemistry (IHC), CCK-8, colony formation, flow cytometry, wound healing, Transwell, and dual-luciferase reporter assays were performed, and xenograft mouse models were established to explore the role of TRAIP in TNBC. This study showed that the expression of TRAIP protein was upregulated in TNBC tissues and cell lines. Silencing of TRAIP significantly inhibited the proliferation, migration, and invasion of TNBC cells, whereas opposite results were observed in the TRAIP overexpression. In addition, TRAIP regulated cell proliferation, migration, and invasion through RB-E2F signaling and epithelial mesenchymal transformation (EMT). MiR-590-3p directly targeted the TRAIP 3'-UTR, and its expression were lower in TNBC tissues. Its mimic significantly downregulated the expression of TRAIP and subsequently suppressed cell proliferation, migration, and invasion. Rescue experiments indicated that TRAIP silencing reversed the promotion of miR-590-3p inhibitor on cell proliferation, migration, and invasion. TRAIP overexpression could also reverse the inhibition of miR-590-3p mimic on tumorigenesis. Finally, TRAIP knockdown significantly inhibited tumor growth and metastasis in animal experiments. In conclusion, TRAIP is an oncogene that influences the proliferation, migration, and invasion of TNBC cells through RB-E2F signaling and EMT. Therefore, TRAIP may be a potential therapeutic target for TNBC.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36064576     DOI: 10.1038/s41417-022-00517-7

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.854


  58 in total

1.  Increased metastasis with loss of E2F2 in Myc-driven tumors.

Authors:  Inez Yuwanita; Danielle Barnes; Michael D Monterey; Sandra O'Reilly; Eran R Andrechek
Journal:  Oncotarget       Date:  2015-11-10

Review 2.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

3.  A progression puzzle.

Authors:  René Bernards; Robert A Weinberg
Journal:  Nature       Date:  2002-08-22       Impact factor: 49.962

Review 4.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

Review 5.  Breast cancer.

Authors:  Nadia Harbeck; Frédérique Penault-Llorca; Javier Cortes; Michael Gnant; Nehmat Houssami; Philip Poortmans; Kathryn Ruddy; Janice Tsang; Fatima Cardoso
Journal:  Nat Rev Dis Primers       Date:  2019-09-23       Impact factor: 52.329

Review 6.  Emerging roles of E2Fs in cancer: an exit from cell cycle control.

Authors:  Hui-Zi Chen; Shih-Yin Tsai; Gustavo Leone
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 8.  Targeting the RB-E2F pathway in breast cancer.

Authors:  J Johnson; B Thijssen; U McDermott; M Garnett; L F A Wessels; R Bernards
Journal:  Oncogene       Date:  2016-02-29       Impact factor: 9.867

Review 9.  Understanding Patterns of Brain Metastasis in Triple-Negative Breast Cancer and Exploring Potential Therapeutic Targets.

Authors:  Yan Lv; Xiao Ma; Yuxin Du; Jifeng Feng
Journal:  Onco Targets Ther       Date:  2021-01-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.